Pfizer rides Paxlovid sales to better-than-expected quarter

KIFI

Published November 1, 2022 5:57 AM

By TOM MURPHY
AP Health Writer

Pfizer’s COVID-19 treatment helped the pharmaceutical giant balance tumbling international sales for its coronavirus vaccine and top third-quarter expectations. The pill treatment Paxlovid brought in $7.5 billion in sales in the quarter and has generated more than $17 billion so far this year. Sales from the vaccine Comirnaty, meanwhile, tumbled 66% to $4.4 billion in the quarter. That was mainly due to changes in a European Commission supply agreement that pushed dose deliveries into the fourth quarter. Sales also were hurt by slow demand in emerging markets. Overall, Pfizer’s profit jumped 6% to $8.61 billion in the third quarter.

Article Topic Follows: AP National Business

Jump to comments ↓

Associated Press

BE PART OF THE CONVERSATION

KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.